Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1968 2
1970 2
1971 1
1972 1
1973 4
1974 5
1975 3
1976 15
1977 5
1978 5
1979 18
1980 40
1981 28
1982 39
1983 28
1984 38
1985 35
1986 45
1987 45
1988 52
1989 44
1990 59
1991 39
1992 38
1993 49
1994 41
1995 48
1996 41
1997 35
1998 29
1999 39
2000 35
2001 32
2002 47
2003 56
2004 54
2005 42
2006 35
2007 35
2008 41
2009 42
2010 49
2011 47
2012 53
2013 81
2014 71
2015 96
2016 117
2017 109
2018 122
2019 99
2020 96
2021 109
2022 92
2023 77
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

2,341 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hypercholesterolemia, autosomal dominant, type B"
Page 1
Familial hypercholesterolemia.
Bouhairie VE, Goldberg AC. Bouhairie VE, et al. Cardiol Clin. 2015 May;33(2):169-79. doi: 10.1016/j.ccl.2015.01.001. Cardiol Clin. 2015. PMID: 25939291 Free PMC article. Review.
Familial hypercholesterolaemia.
Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Defesche JC, et al. Nat Rev Dis Primers. 2017 Dec 7;3:17093. doi: 10.1038/nrdp.2017.93. Nat Rev Dis Primers. 2017. PMID: 29219151 Review.
Cascade screening can contribute to early diagnosis of the disease in family members of an affected individual, which is crucial because familial hypercholesterolaemia can be asymptomatic for decades. Clinical severity depends on the nature of the gene that harbours the ca …
Cascade screening can contribute to early diagnosis of the disease in family members of an affected individual, which is crucial because fam …
Familial Hypercholesterolemia: Global Burden and Approaches.
Tokgozoglu L, Kayikcioglu M. Tokgozoglu L, et al. Curr Cardiol Rep. 2021 Sep 4;23(10):151. doi: 10.1007/s11886-021-01565-5. Curr Cardiol Rep. 2021. PMID: 34480646 Review.
In most cases, mutations in the LDL-receptor (LDLR) gene and to a lesser degree in the apolipoprotein B-100 (APOB), proprotein convertase subtilisin/kexin type 9 (PCSK9), and the LDL-receptor adaptor protein 1 (LDLRAP1) genes cause FH. Diagnostic scores such as Dutch Lipid …
In most cases, mutations in the LDL-receptor (LDLR) gene and to a lesser degree in the apolipoprotein B-100 (APOB), proprotein convertase su …
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Friedman A, Wijngaard PLJ, Garcia Conde L, Kastelein JJP; ORION Phase III Investigators. Wright RS, et al. J Am Coll Cardiol. 2021 Mar 9;77(9):1182-1193. doi: 10.1016/j.jacc.2020.12.058. J Am Coll Cardiol. 2021. PMID: 33663735 Free article.
BACKGROUND: Inclisiran is a double-stranded small interfering RNA that suppresses proprotein convertase subtilisin-kexin type 9 (PCSK9) translation in the liver, leading to sustained reductions in low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoprotei …
BACKGROUND: Inclisiran is a double-stranded small interfering RNA that suppresses proprotein convertase subtilisin-kexin type 9 (PCSK …
Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis.
Barkas F, Nomikos T, Liberopoulos E, Panagiotakos D. Barkas F, et al. Nutrients. 2020 Aug 13;12(8):2436. doi: 10.3390/nu12082436. Nutrients. 2020. PMID: 32823643 Free PMC article.
SEARCH METHODS: Relevant trials were identified by searching US National Library of Medicine National Institutes of Health Metabolism Trials Register and clinicaltrials.gov.gr using the following terms: diet, dietary, plant sterols, stanols, omega-3 fatty acids, fiber and familia …
SEARCH METHODS: Relevant trials were identified by searching US National Library of Medicine National Institutes of Health Metabolism Trials …
Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects.
Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Beheshti SO, et al. J Am Coll Cardiol. 2020 May 26;75(20):2553-2566. doi: 10.1016/j.jacc.2020.03.057. J Am Coll Cardiol. 2020. PMID: 32439005 Free article.
METHODS: In this systematic review and meta-analyses, Embase, PubMed, and the Web of Science were searched until June 3, 2019, for peer-reviewed papers and conference abstracts reporting heterozygous FH prevalence in nonfounder populations, revealing 104 studies eligible for incl …
METHODS: In this systematic review and meta-analyses, Embase, PubMed, and the Web of Science were searched until June 3, 2019, for peer-revi …
Familial hypercholesterolemia.
Sawhney JPS, Madan K. Sawhney JPS, et al. Indian Heart J. 2024 Mar;76 Suppl 1(Suppl 1):S108-S112. doi: 10.1016/j.ihj.2023.12.002. Epub 2024 Apr 8. Indian Heart J. 2024. PMID: 38599725 Free PMC article. Review.
Inspite of maximum dose of statin with or without Ezetimibe, if target levels of LDL-C are not achieved, Bempedoic acid, proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibitors/Inclisiran can be added....
Inspite of maximum dose of statin with or without Ezetimibe, if target levels of LDL-C are not achieved, Bempedoic acid, proprotein converta …
Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms.
Kallapur A, Sallam T. Kallapur A, et al. Trends Cardiovasc Med. 2023 Apr;33(3):170-179. doi: 10.1016/j.tcm.2021.12.011. Epub 2021 Dec 27. Trends Cardiovasc Med. 2023. PMID: 34968676 Free article. Review.
In this state-of-the-art review, we explore the development, clinical efficacy and limitations of existing and potential future therapeutics in familial hypercholesterolemia....
In this state-of-the-art review, we explore the development, clinical efficacy and limitations of existing and potential future thera …
Screening and management of familial hypercholesterolemia.
Santos RD. Santos RD. Curr Opin Cardiol. 2019 Sep;34(5):526-530. doi: 10.1097/HCO.0000000000000660. Curr Opin Cardiol. 2019. PMID: 31393421 Review.
Molecular diagnosis is recommended but still not widely available and reimbursed, also recent reclassification of genetic variants associated with familial hypercholesterolemia limits its routine use. New familial hypercholesterolemia clinical diagnostic criteria like FAMC …
Molecular diagnosis is recommended but still not widely available and reimbursed, also recent reclassification of genetic variants associate …
2,341 results